<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887418</url>
  </required_header>
  <id_info>
    <org_study_id>QST-13-002</org_study_id>
    <nct_id>NCT01887418</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Testosterone Enanthate</brief_title>
  <official_title>3 Arm Open-label Randomized Multidose Study of Pharmacokinetics, Safety &amp; Tolerability of Testosterone Enanthate Administered Subcutaneously Via an Auto-injector Device or Intramuscular Testosterone Enanthate in Hypogonadal Adult Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antares Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antares Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard Pharmacokinetic (PK) analyses of data for serum testosterone were done. Cmax, Area
      Under Curve (AUC), and Cavg were used for the comparison of relative bioavailability of the
      treatments and reference arm.

      Safety comparisons were based upon the occurrence, severity and rate of treatment emergent
      adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post-dose, at 6 Weeks</time_frame>
    <description>The area under the curve from time zero to last quantifiable concentration [AUC (0-t)] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum Plasma Concentration [Cmax] of Testosterone Enanthate Formulations at 6 Weeks</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post-dose, at 6 Weeks</time_frame>
    <description>The maximum observed plasma concentration [Cmax] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Average Concentration [Cavg] of Testosterone Enanthate Formulations at 6 Weeks</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post-dose, at 6 Weeks</time_frame>
    <description>The average concentration [Cavg] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in the PK Parameter Category</measure>
    <time_frame>6 weeks</time_frame>
    <description>The number of TT Cavg (0-168h) values within the normal range (300-1100 ng/dL) following treatment with SC TE administered via QST or IM TE</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>QuickShot™ - 100 mg Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QuickShot™Testosterone - Auto-injector device for SC use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QuickShot™ - 50 mg Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QuickShot™Testosterone- Auto-injector device for SC use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delatestryl 200 mg IM Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QuickShot™ - 50 mg Treatment B</intervention_name>
    <description>QuickShot™ for the delivery of testosterone</description>
    <arm_group_label>QuickShot™ - 50 mg Treatment B</arm_group_label>
    <other_name>Testosterone</other_name>
    <other_name>Testosterone enanthate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QuickShot™ - 100 mg Treatment A</intervention_name>
    <description>QuickShot™ for the delivery of testosterone</description>
    <arm_group_label>QuickShot™ - 100 mg Treatment A</arm_group_label>
    <other_name>Testosterone</other_name>
    <other_name>Testosterone enanthate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delatestryl 200 mg IM Treatment C</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Delatestryl 200 mg IM Treatment C</arm_group_label>
    <other_name>Testosterone</other_name>
    <other_name>Testosterone enanthate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males aged 18 to 75 with a documented diagnosis of hypogonadism

        Exclusion Criteria:

          -  Normal testosterone levels

          -  Subjects with any clinically significant medical condition which, in the opinion of
             the Investigator, would make the subject an unsuitable candidate for enrollment in the
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Bedel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prestige Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mens Health Boston</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <results_first_submitted>July 20, 2015</results_first_submitted>
  <results_first_submitted_qc>September 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2015</results_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Testosterone enanthate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened at 10 sites in USA. In total, 39 eligible subjects were enrolled and received study medication (investigational SC QST or IM RLD): 14 subjects in 50 mg SC QST arm, 15 subjects in 100 mg SC QST arm and 10 subjects in 200 mg IM RLD arm.</recruitment_details>
      <pre_assignment_details>Eligible patients were randomized to receive SC 50mg (Treatment B) or SC 100mg (Treatment A) QST and the subject who were on IM testosterone replacement therapy, received IM TE RLD (Treatment C).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QuickShot™ - 100 mg Treatment A</title>
          <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 100 mg Treatment A: QuickShot™ for the delivery of testosterone once a week</description>
        </group>
        <group group_id="P2">
          <title>QuickShot™ - 50 mg Treatment B</title>
          <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 50 mg Treatment B: QuickShot™ for the delivery of testosterone once a week.</description>
        </group>
        <group group_id="P3">
          <title>Delatestryl 200 mg IM Treatment C</title>
          <description>Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
Delatestryl 200 mg IM Treatment C: injected once only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Travelling difficulties</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Population (39 subjects) was all randomized subjects who received at least 1 dose of investigational product.
The PK Population (39 subjects) was all subjects from Safety Population who did not have a major protocol deviation that impacted the integrity of PK data and had at least 1 valid post-dose plasma concentration value.</population>
      <group_list>
        <group group_id="B1">
          <title>QuickShot™ - 100 mg Treatment A</title>
          <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 100 mg Treatment A: QuickShot™ for the delivery of testosterone once a week for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>QuickShot™ - 50 mg Treatment B</title>
          <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 50 mg Treatment B: QuickShot™ for the delivery of testosterone once a week for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Delatestryl 200 mg IM Treatment C</title>
          <description>Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
Delatestryl 200 mg IM Treatment C: injected once only</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="12.80"/>
                    <measurement group_id="B2" value="54.0" spread="12.42"/>
                    <measurement group_id="B3" value="48.9" spread="10.94"/>
                    <measurement group_id="B4" value="52.9" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) at screening (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.19" spread="2.87"/>
                    <measurement group_id="B2" value="28.51" spread="2.17"/>
                    <measurement group_id="B3" value="29.05" spread="2.21"/>
                    <measurement group_id="B4" value="28.91" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Total Testosterone (TT) (ng/dL)</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201.50" spread="71.53"/>
                    <measurement group_id="B2" value="214.64" spread="59.05"/>
                    <measurement group_id="B3" value="735.10" spread="187.96"/>
                    <measurement group_id="B4" value="343.04" spread="256.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in the PK Parameter Category</title>
        <description>The number of TT Cavg (0-168h) values within the normal range (300-1100 ng/dL) following treatment with SC TE administered via QST or IM TE</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>QuickShot™ - 100 mg Treatment A</title>
            <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 100 mg Treatment A: QuickShot™ for the delivery of testosterone</description>
          </group>
          <group group_id="O2">
            <title>QuickShot™ - 50 mg Treatment B</title>
            <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 50 mg Treatment B: QuickShot™ for the delivery of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Delatestryl 200 mg IM Treatment C</title>
            <description>Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
Delatestryl 200 mg IM Treatment C: Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in the PK Parameter Category</title>
          <description>The number of TT Cavg (0-168h) values within the normal range (300-1100 ng/dL) following treatment with SC TE administered via QST or IM TE</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks</title>
        <description>The area under the curve from time zero to last quantifiable concentration [AUC (0-t)] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post-dose, at 6 Weeks</time_frame>
        <population>PK profile of TT obtained at Week 6 of treatment by QST</population>
        <group_list>
          <group group_id="O1">
            <title>QuickShot™ - 100 mg Treatment A</title>
            <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 100 mg Treatment A: QuickShot™ for the delivery of testosterone</description>
          </group>
          <group group_id="O2">
            <title>QuickShot™ - 50 mg Treatment B</title>
            <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 50 mg Treatment B: QuickShot™ for the delivery of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Delatestryl 200 mg IM Treatment C</title>
            <description>Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
Delatestryl 200 mg IM Treatment C: Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks</title>
          <description>The area under the curve from time zero to last quantifiable concentration [AUC (0-t)] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
          <population>PK profile of TT obtained at Week 6 of treatment by QST</population>
          <units>ng*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150445.2" spread="46998.76"/>
                    <measurement group_id="O2" value="70955.7" spread="20815.18"/>
                    <measurement group_id="O3" value="278657.9" spread="168295.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Maximum Plasma Concentration [Cmax] of Testosterone Enanthate Formulations at 6 Weeks</title>
        <description>The maximum observed plasma concentration [Cmax] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post-dose, at 6 Weeks</time_frame>
        <population>PK profile of TT obtained at Week 6 of treatment by QST</population>
        <group_list>
          <group group_id="O1">
            <title>QuickShot™ - 100 mg Treatment A</title>
            <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 100 mg Treatment A: QuickShot™ for the delivery of testosterone</description>
          </group>
          <group group_id="O2">
            <title>QuickShot™ - 50 mg Treatment B</title>
            <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 50 mg Treatment B: QuickShot™ for the delivery of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Delatestryl 200 mg IM Treatment C</title>
            <description>Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
Delatestryl 200 mg IM Treatment C: Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Plasma Concentration [Cmax] of Testosterone Enanthate Formulations at 6 Weeks</title>
          <description>The maximum observed plasma concentration [Cmax] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
          <population>PK profile of TT obtained at Week 6 of treatment by QST</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1345.6" spread="435.63"/>
                    <measurement group_id="O2" value="622.4" spread="129.51"/>
                    <measurement group_id="O3" value="261.9" spread="1310.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Average Concentration [Cavg] of Testosterone Enanthate Formulations at 6 Weeks</title>
        <description>The average concentration [Cavg] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post-dose, at 6 Weeks</time_frame>
        <population>PK profile of TT obtained at Week 6 of treatment by QST</population>
        <group_list>
          <group group_id="O1">
            <title>QuickShot™ - 100 mg Treatment A</title>
            <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 100 mg Treatment A: QuickShot™ for the delivery of testosterone</description>
          </group>
          <group group_id="O2">
            <title>QuickShot™ - 50 mg Treatment B</title>
            <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 50 mg Treatment B: QuickShot™ for the delivery of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Delatestryl 200 mg IM Treatment C</title>
            <description>Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
Delatestryl 200 mg IM Treatment C: Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>The Average Concentration [Cavg] of Testosterone Enanthate Formulations at 6 Weeks</title>
          <description>The average concentration [Cavg] of TE administered by SC injection once weekly at doses of 50 mg and 100 mg via the QST</description>
          <population>PK profile of TT obtained at Week 6 of treatment by QST</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="895.5" spread="279.75"/>
                    <measurement group_id="O2" value="422.4" spread="123.90"/>
                    <measurement group_id="O3" value="1658.7" spread="1001.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were classified as any adverse events that occurred from Day1 (after screening) to a given treatment period until the subject completed the study. The duration of the study participation for subjects was approximately 19 weeks.</time_frame>
      <desc>The Safety Population was defined as all randomized subjects who received at least 1 dose of investigational product. The safety population was 39 subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>QuickShot™ - 100 mg Treatment A</title>
          <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 100 mg Treatment A: QuickShot™ for the delivery of testosterone once a week</description>
        </group>
        <group group_id="E2">
          <title>QuickShot™ - 50 mg Treatment B</title>
          <description>QuickShot™ - Auto-injector device for SC use
QuickShot™ - 50 mg Treatment B: QuickShot™ for the delivery of testosterone once a week.</description>
        </group>
        <group group_id="E3">
          <title>Delatestryl 200 mg IM Treatment C</title>
          <description>Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
Delatestryl 200 mg IM Treatment C: injected once only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site hemorrhage*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Jaffe, MD; Vice President Clinical Development</name_or_title>
      <organization>Antares Pharma Inc.</organization>
      <phone>609-329-3020 ext 324</phone>
      <email>jjaffe@antarespharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

